A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of ReoCure as Monotherapy and in Combination with Keytruda (Pembrolizumab) in Patients with Advanced Malignant Solid Tumours
Latest Information Update: 10 Jun 2024
At a glance
- Drugs Pembrolizumab (Primary) ; ReoCure (Primary)
- Indications Cancer metastases; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors ViroCure
- 10 Apr 2024 Status changed from not yet recruiting to recruiting.
- 05 Aug 2020 New trial record